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Abstract 
The causes of cancer health disparities amongst Pacific Islanders and other racial groups are complex and 
multifactorial. Both biologic and non biologic determinants have been identified as causal factors. 
Racial/ethnic classification can be used as a surrogate for non biologic determinants such as place of 
geographic origin, socioeconomic status, cultural practices, and diet.  Given that non biologic and 
biologic determinants are not mutually exclusive, using racial/ethnic classification may be hypothesis 
generating and assist in the identification of biologic determinants such as infections, toxins, and/or 
environmental exposures that lead to carcinogenesis. This commentary provides several examples of 
cancer specific biologic determinants that may lead to cancer health disparities. It also discusses specific 
non biologic determinants of cancer health disparities that must be overcome in order to increase 
participation of underserved populations in clinical trial research. Taken together, these examples 
demonstrate the need to further our understanding of the determinants of cancer health disparities that can 
lead to the enactment of preventive measures and/or targeted therapies. 
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Introduction 
 
The causes of cancer health disparities in 
underserved populations such as Pacific 
Islanders are multifactorial and complex 
(Palafox, Buenconsejo-Lum et al. 2002; Tsark 
and Braun 2007; Tanjasiri and Tran 2008).  
Medical advancements that have been made in 
the early detection, diagnosis, and treatment of 
cancer have not been realized by all racial/ethnic 
groups in our society (Brawley and Berger 2008; 
Goss, Lopez et al. 2009).  Although Pacific 
Islander-specific data is lacking, determinants of 
cancer health disparities as identified from other 
populations can be generally categorized into 
biologic and non biologic factors.  The most 
identifiable and better understood causes of 
cancer health disparities are non biologic 
determinants including lack of access to quality 
health care, cultural barriers between health care 
providers and patients, and lack of education.  
The articles in this issue of the Journal document 
efforts within different Pacific Islander 
communities in Southern California to further 
understand and resolve some of these disparities.  
These efforts predominately focus on 
overcoming non biologic determinants of cancer 
health disparities.  This paper will describe 
recently identified potential biologic 
determinants that may lead to differences in 
cancer outcomes between racial groups, 
including Pacific Islanders.  As biologic and non 
biologic determinants are not mutually 
exclusive, it will also discuss some of the 
important non biologic factors that need to be 
addressed in order to increase our understanding 
of, and identify solutions for, this complex 
problem. 
 
Using Racial/Ethnic Classifications to 
Identify Potential Biologic Determinants 
Recently, several articles have been published 
attempting to identify biologic determinants of 
racial disparities by analyzing data collected on 
participants in National Cancer Institute (NCI)-
sponsored cooperative group clinical trials. The 
Beale, K.K. / Californian Journal of Health Promotion 2010, Special Issue (Cancer Control), 101 - 111 
 
 102 
advantage of analyzing clinical trial data 
includes standardized enrollment criteria, 
treatment, and follow-up. The largest study 
reported on over 19,000 adult cancer patients 
enrolled in Southwest Oncology Group (SWOG) 
randomized phase III clinical trials from October 
1, 1974 through November 29, 2001 (Albain, 
Unger et al. 2009). Nearly 12% identified 
themselves as African Americans. After 
adjustment for prognostic, treatment, and 
socioeconomic factors, African American race 
was associated with increased mortality from 
early-stage premenopausal breast cancer, early-
stage postmenopausal breast cancer, advanced-
stage ovarian cancer, and advanced-stage 
prostate cancer but not from lung cancer, colon 
cancer, lymphoma, leukemia, or myeloma. The 
authors concluded that their findings “suggest 
that unrecognized interactions of tumor 
biological, hormonal, and/or inherited host 
factors must be contributing to differential 
survival outcomes by race (page 991).” 
 
As Brawley aptly points out in his editorial 
(Brawley 2009), as well as in several 
correspondences sent to the editor, there are 
definite limitations to this study (Rosenberg, 
Maneshe, et al. 2010; Gravlee and Mulligan 
2010). These commentaries discussed potential 
confounders in their study such as using zip 
code area income and education data as 
surrogates for socioeconomic status (SES) and 
not adjusting for racial differences in body mass 
index (BMI). Higher BMI has been linked to 
higher risk of ovarian and breast cancer (Huang, 
Hankinson et al. 1997; Renehan, Tyson et al. 
2008; Leitzmann, Koebnick et al. 2009). 
Interestingly, a similar analysis done on 97 black 
women and 1392 white women with advanced 
ovarian cancer enrolled in Gynecologic 
Oncology Group (GOG) randomized clinical 
trials did not demonstrate significant differences 
in survival outcomes by race (Farley, Tian et al. 
2009). 
 
So what can we conclude from these recent 
reports? Can we say that African Americans and 
Caucasians enrolled on a clinical trial and given 
similar treatment will have similar outcomes? Or 
will one group have worse outcomes compared 
to the other despite similar treatments? My 
answers are “yes”, and “yes.” As we are learning 
more about the biology of tumors we are finding 
that not all cancers are created equally. As we 
probe the genetic and molecular make up of 
these cancers we find that certain characteristics 
can portend to either higher or lower 
probabilities of response to therapy, risk of 
relapse, and overall survival. But what causes 
these genetic and biological differences? In 
almost all cases we do not know, but most 
genetic mutations found in cancers are somatic 
mutations and not germ-line mutations, meaning 
they are acquired mutations and not inherited 
(DeVita, Lawrence et al. 2008). It would not be 
surprising to find that certain racial groups, such 
as Pacific Islanders, have a higher proportion of 
mutations with either higher risk or lower risk 
mutations that may partially explain the 
differences in outcomes that are apparent 
amongst racial groups. Race, as Brawley points 
out (Brawley 2009), “is not a scientific 
categorization…it is more scientific to think of 
race as a surrogate for area of geographic origin, 
socioeconomic status (SES), and culture, all of 
which can have correlations with disease risk 
(page 970).” Race then is a surrogate for non 
biologic determinants of disease and is not a 
scientific descriptor (Brawley and Berger, 2008).  
However, as non biologic and biologic 
determinants are not mutually exclusive, using 
racial/ethnic classification may be hypothesis 
generating and assist in the identification of 
biologic determinants. An improved 
understanding of biologic determinants may 
enable us to identify causal factors. Factors such 
as infections, toxins, and/or environmental 
exposures that are associated with area of 
geographic origin, SES, cultural practices, diet 
or other factors associated with race/ethnicity 
that may provide opportunities for interventions 
to eliminate these carcinogens. The next section 
gives examples in which biologic determinants 
may contribute to cancer health disparities 
(Table 1). 
 
Biologic Determinants of Cancer Health 
Disparities 
Specific examples of biologic determinants in 
breast, gastric, oral pharyngeal, hepatocellular 
and lung cancers among Pacific Islanders and 
other ethnic groups demonstrate the value of  
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further epidemiologic, laboratory, and clinical 
research in underserved and underrepresented 
populations in order to advance our 
understanding of the complex interactions that 
are leading to carcinogenesis.  
 
Breast Cancer 
Native Hawaiian women have the highest breast 
cancer incidence and mortality rates compared 
to Hawaii’s other major racial/ethnic groups 
(Braun, Fong, et al. 2004). For years we have 
known that breast cancer is a heterogeneous 
disease with several different subtypes that have 
significant differences in prognosis and response 
to therapy (DeVita, Lawrence et al. 2008). 
Breast cancer patients whose tumors lack 
expression of estrogen receptors (ER-) and 
progesterone receptors (PR-) represent 
approximately 20-30% of breast cancer cases. 
ER-/PR- tumors do not respond to hormonal 
therapy and these patients have a worse  
 
 
prognosis. A majority of these patients will also 
be negative for the human epidermal growth 
factor receptor 2 (Her2-). Tumors lacking Her2 
expression do not respond to targeted Her2 
therapies such as trastuzumab (Herceptin
®
) or 
lapatinib (Tykerb
®
). Recent molecular 
characterization of breast cancer tumors has 
identified ER-/PR-/Her2- tumors, also known as 
basal-like tumors, as being an aggressive 
subtype with the poorest prognosis (Sorlie, 
Perou, et al. 2001). Premenopausal African 
American women have been found to have the 
highest rates of basal-like tumors (39%) 
compared to premenopausal non African 
American women (16%) (Carey, Perou, et al. 
2006). Of note however, a recent study of the 
SEER database found that even when taking into 
account tumor characteristics, such as hormone 
receptor status, racial disparities persist 
(Maneshe, Anderson, et al. 2009; Rosenberg, 
Maneshe, et al. 2010). Other non biologic  
 
 
Table 1 
 
Examples of biologic determinants that may contribute to cancer health disparities 
Tumor Type Biologic Determinant 
Racial/Ethnic Differences in 
Biologic Determinants 
Racial/Ethnic Cancer 
Disparity 
Breast Cancer 
Estrogen/progesterone receptor negative 
(ER-/PR-) breast cancer patients have a 
worse prognosis 
↑ incidence of ER-/PR- breast 
cancer in African American 
(AA) women 
 
↓ incidence of ER-/PR- breast 
cancer in Native Hawaiian (NH) 
women, other determinants must 
be contributing 
Worse breast cancer 
outcomes for AA and 
NH women 
Gastric Cancer 
H. pylori infection and diets high in 
nitrosamines are associated with gastric 
cancer 
H. pylori infection and diets 
high in nitrosamines may 
contribute to gastric cancer in 
Asian/Pacific Islanders (API) 
↑ incidence of gastric 
cancer in API 
Oral Pharyngeal 
Cancer (OPC) 
Improved outcome of human 
papillomavirus (HPV) positive OPC 
compared to HPV negative OPC 
↑ incidence of HPV positive 
OPC in Caucasians compared to 
AA 
Worse OPC outcomes 
in AA compared to 
Caucasians 
Hepatocellular 
carcinoma (HCC) 
Improved outcome of hepatitis C 
associated HCC treated with sorafenib 
compared to hepatitis B associated HCC 
↑incidence of hepatitis B 
associated HCC in API 
A new treatment that 
may lead to further 
cancer disparities 
Non Small Cell 
Lung Cancer 
(NSCLC) 
Improved outcome of EGFR mutated 
NSCLC treated with an EGFR tyrosine 
kinase inhibitor compared to EGFR wild 
type NSCLC 
↑ incidence of EGFR mutations 
in East Asians 
A new treatment that 
may lead to further 
cancer disparities 
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factors, such as access to quality cancer care 
and/or yet to be determined biologic factors 
likely contribute to this disparity. 
 
The Multiethnic Cohort study has also analyzed 
breast cancer hormone receptor status in other 
racial groups including Japanese and Native 
Hawaiians living in California and Hawaii 
(Setiawan, Monroe, et al. 2009). ER-/PR- 
tumors were most common in African 
Americans
 
(31%), followed by Latinas (25%), 
Whites (18%), Japanese (14%),
 
and Native 
Hawaiians (14%). Despite the lower rate of ER-
/PR- tumors, Native Hawaiian women have the 
worst breast cancer mortality rate compared to 
Hawaii’s other major racial/ethnic groups 
(Braun, Fong, et al. 2004). Breast cancer health 
disparities persisted after controlling for age, 
stage, and ER/PR status (Braun, Fong, et al. 
2004; Braun, Fong, et al. 2005). Comparatively, 
the biologic determinants of breast cancer 
disparities between African Americans and 
Native Hawaiians appear to be different. This 
exemplifies the complexity of cancer health 
disparities in that different racial/ethnic groups 
may or may not share biologic and/or non 
biologic determinants. 
 
Gastric Cancer 
Incidence rates of gastric cancer are higher 
amongst Pacific Islanders and Asian Americans 
compared to other racial groups (Brawley and 
Berger 2008; Miller, Chu et al. 2008). In the 
1980’s, a gram negative spiral bacteria called 
Helicobacter pylori (H. pylori) was initially 
described in patients with gastritis and peptic 
ulceration (Marshall and Warren 1984). Further 
epidemiologic studies would later identify an 
association between gastric cancer and H. pylori 
infection (IARC 1994; Nomura, Kolonel et al. 
2005). However, only a minority of H. pylori 
infected cases have been found to develop 
gastric cancer (Correa and Houghton 2007). It 
has become evident that other environmental or 
host carcinogenic factors must be involved. 
Epidemiologic studies have identified an 
association between gastric cancer and the 
increased consumption of nitrosamine 
containing compounds found in pickled foods, 
smoked, and processed meats (Kolonel, Nomura 
et al. 1981; Jakszyn, Bingham et al. 2006). A 
recent five-year prospective dietary study in 
rhesus monkeys found a synergistic carcinogenic 
effect in those monkeys infected with H. pylori 
and given a diet high in nitrosamines compared 
with either alone (Liu, Merrell et al. 2009). 
Interestingly, the increased incidence of gastric 
cancer in East Asian countries geographically 
correlates with an endemic H. pylori subtype 
(Yamaoka, Kato et al. 2008). This subtype of H. 
pylori has also been found to have a greater 
carcinogenic potential when compared to other 
subtypes in a mouse model (Miura, Ohnishi et 
al. 2009). These findings would suggest that the 
higher incidence of gastric cancer in Asian 
Americans and Pacific Islanders may be related 
to the carcinogenic effects of dietary nitrosamine 
intake and H. pylori infections that are endemic 
to areas of geographic origin. It also begins to 
identify populations at increased risk for gastric 
cancer for whom screening and preventive 
strategies, such as dietary modification and H. 
pylori eradication, may be effective in 
decreasing cancer health disparities. 
 
Oral Pharyngeal Cancer (OPC) 
OPC is a subset of head and neck cancer. Pacific 
Islanders and African Americans have a higher 
incidence and mortality rate of OPC compared 
to other ethnic groups (Brawley and Berger 
2008; Haddock, 2005). Human papillomaviruses 
(HPV) are known causes of anal and cervical 
cancer (Devita, Lawrence et al. 2008).  HPV is 
transmitted through unprotected vaginal, anal, or 
oral sex. Recently, HPV infection has been 
identified as a causative agent of OPC (D'Souza, 
Kreimer, et al. 2007; Mork, Lie, et al. 2001). 
Interestingly, patients with HPV positive OPC 
have an improved therapeutic response and 
survival compared to HPV negative OPC 
(Fakhry, Westra et al. 2008). In a retrospective 
study of a randomized phase III trial in patients 
with head and neck cancer the racial outcome 
disparity in overall survival between African 
Americans and Caucasians was entirely due to 
the disparity in the subset of patients with OPC 
(Settle, Posner et al. 2009). HPV-positive 
tumors were detected in 34% of Caucasian 
patients compared to only 4% in African 
American patients. Thus, it appears that the 
cancer health disparity between African 
Americans and Caucasians with OPC who 
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receive equal quality cancer care can be 
explained by a higher prevalence of treatment 
sensitive HPV positive tumors in Caucasians 
compared to African Americans. 
 
So how do we account for the difference in HPV 
incidence in OPC between Caucasians and 
African Americans? A US national survey of 
adolescent males found that Caucasian males 
were 2.7 times more likely to engage in oral sex 
compared to African American males and were 
1.4 times more likely to receive oral sex from a 
female (Brawley 2009; Gates and Sonenstein 
2000). Another national survey found that 
Caucasian adolescent females were twice as 
likely as African American females to engage in 
oral sex (Brawley 2009). These surveys would 
suggest that the increased prevalence of HPV 
positive OPC in Caucasians may be attributable 
to higher rates of oral sex practices compared to 
African Americans. More importantly these 
findings support enactment of measures (HPV 
vaccination, education) to prevent HPV 
infection and subsequent OPC for all sexually 
active people. To my knowledge, the proportion 
of HPV positive OPC in Pacific Islanders has 
not been reported. 
 
Hepatocellular Carcinoma (HCC) 
Incidence and mortality rates of HCC amongst 
Pacific Islanders and Asian Americans are also 
significantly higher compared to other racial 
groups (Brawley and Berger 2008; Miller, Chu 
et al. 2008). HCC is a type of cancer that largely 
occurs in patients with liver cirrhosis secondary 
to viral hepatitis B and/or C, alcoholism, or 
other causes of chronic liver damage. Sorafenib 
(Nexavar
®
) is an oral multi-kinase inhibitor that 
was recently studied in a randomized placebo 
controlled phase III clinical trial of 602 patients 
with advanced HCC. Participating centers were 
mostly located in the United States (US) and 
Europe. The sorafenib treated group 
demonstrated an increase in median overall 
survival of 10.7 months compared to 7.9 months 
in the placebo group (p<0.001) (Llovet, Ricci et 
al. 2008). A similar phase III clinical trial 
enrolling patients from Asia demonstrated 
improvement in median overall survival in the 
sorafenib treated group from 4.1 to 6.2 months 
(Cheng, Kang et al. 2008). Although the margin 
of benefit was similar between trials, the patients 
in the Asian study did worse overall. The 
explanation given by the study investigators is 
that the patients in the Asian study had more 
advanced disease based on a higher number of 
tumor sites and lung metastases and poorer 
performance status compared to those on the 
US/European based study. Other factors may be 
contributing to this difference. 
 
It is important to note that the proportion of 
patients with hepatitis B was higher in the Asian 
study. Conversely, the proportion of patients 
with hepatitis C was higher in the US/European 
based study. These patients appear to have an 
improved response to sorafenib compared to 
patients with hepatitis B or alcoholic cirrhosis 
based on a subgroup analysis which 
demonstrated a median overall survival of 14.0 
months with sorafenib therapy versus 7.9 
months with placebo (Bolondi, Caspary et al. 
2008). Ongoing research may provide further 
insight as to the role that race and hepatitis virus 
subtypes may play in the sorafenib treatment 
outcomes of advanced HCC. If hepatitis B 
associated HCC patients have a decreased 
response to sorafenib compared to hepatitis C 
associated HCC patients, this may in fact 
increase cancer health disparities. However, it 
may also provide evidence that the development 
of hepatitis and carcinogenic pathways in HCC 
differs depending upon the causative 
mechanisms involved. 
 
Lung Cancer. 
Lung cancer is divided based on tumor tissue 
histology into two types, small cell lung cancer 
and non small cell lung cancer (NSCLC) 
(DeVita, Lawrence et al. 2008). NSCLC makes 
up a heterogeneous group of several different 
histological subtypes including adenocarcinoma 
and squamous cell carcinoma. Recently, it has 
been found that specific mutations of the 
epidermal growth factor receptor (EGFR) gene 
correlates with increased sensitivity and 
improved response to drugs that inhibit EGFR 
tyrosine kinase activity (Lynch, Bell et al. 2004). 
An analysis of lung tumor samples from the US, 
Japan, Taiwan, and Australia found that these 
mutations are significantly more common in 
patients of East Asian ethnicity versus
 
other 
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ethnicities (30% versus 8%) (Shigematsu, Lin et 
al. 2005). These mutations were also more 
common in never smokers versus ever smokers 
(51% versus
 
10%), in adenocarcinomas versus 
cancer of other histologies
 
(40% and 3%, 
respectively), and in females versus males
 
(42% 
and 14%, respectively). African American lung 
cancer patients also appear to have a lower 
incidence of these mutations (Leidner, Fu, et al. 
2009). To my knowledge, the proportion of 
Pacific Islanders with EGFR mutations has not 
been reported. 
 
A recently reported phase III trial conducted in 
East Asia randomized never smokers or former 
light smokers with metastatic lung 
adenocarcinoma to standard cytotoxic 
chemotherapy versus gefitinib (Iressa®), an oral 
EGFR tyrosine kinase inhibitor (Mok, Wu et al. 
2009).  In this select population the EGFR 
mutation rate was over 50%.  EGFR mutated 
patients treated with gefitinib had a significantly 
longer progression free survival compared to 
EGFR mutated patients treated with cytotoxic 
chemotherapy.  Conversely, EGFR wild type 
patients treated with cytotoxic chemotherapy 
had a significantly longer progression free 
survival compared to EGFR wild type patients 
treated with gefitinib.  The etiology of EGFR 
mutations has yet to be identified.  Further 
defining the subset of patients with these 
mutations may provide insight into potential 
carcinogenic causes of this type of lung cancer.  
Interestingly, this new therapy may actually lead 
to more cancer health disparities. 
 
A better understanding of the causes of acquired 
mutations and carcinogenesis will help us 
identify factors within our environment, i.e., 
diet, toxins, infections, or other exposures, that 
could lead to improved preventive measures and 
a likely decrease in cancer disparities. Currently, 
the lack of participation of underserved 
populations in clinical trials reduces 
opportunities to discover effects that may be 
particularly relevant to these communities and 
contribute to inequitable distribution of benefits 
and risks of trial participation. Pacific Islanders 
comprised only 0.25% of all NCI sponsored 
clinical trials (NCI 2008). Improving clinical 
trial participation will be a vital part in 
extending advances in cancer care to all 
underserved populations. The non biologic 
determinants addressed henceforth contribute to 
the lack of participation of underserved 
populations in clinical trial research. 
 
Non Biologic Determinants Contributing to 
Low Minority Participation in Cancer 
Clinical Trials 
Unfortunately, in the United States today, there 
are several social, political, and economic issues 
facing underserved populations that must be 
resolved if we are going to reduce cancer health 
disparities. It is projected that over the next 20 
years the burden of cancer in the United States is 
expected to increase by 45% between 2010 and 
2030 (Smith, Smith et al. 2009). Most of this 
increase is attributable to an increased incidence 
in older adults and racial minorities. By 2030, 
more than an 100% increase in the incidence of 
most individual cancer sites is projected fpr 
Asian Americans and Pacific Islanders (Smith, 
Smith et al. 2009). These projections exemplify 
the need to further understand and address the 
multiple factors that contribute to cancer health 
disparities. 
 
Quality Health Insurance. 
Pacific Islanders in California have lower rates 
of health insurance coverage compared to 
Caucasians (Brown, Ponce et al. 2001).  From 
2000 to 2005 the percentage of US citizens 
without health insurance continued to increase 
from 14.2% to 15.9% (Goss, Lopez et al. 2009). 
Racial minorities have lower rates of health 
insurance which results in significant barriers to 
receiving health care (Ward, Halpern et al. 
2008). Lack of health insurance is associated 
with lower rates of cancer screening, advanced 
stage at time of cancer diagnosis, and increased 
cancer mortality (Halpern, Ward et al. 2008; 
Ward, Halpern et al. 2008). Patients without 
insurance are also less likely to participate in 
cancer clinical trials (Colon-Otero, Smallridge et 
al. 2008) further limiting our understanding of 
the cancer experience in minorities. The passage 
of the Patient Protection and Affordable Health 
Care Act provides guaranteed health insurance 
for clinical trial participants and removes 
lifetime caps on insurance coverage (ASCO 
2010). These changes should lead to increased 
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participation of minorities in cancer clinical 
trials but how large of an effect this will have is 
unclear. 
 
Improving Patient-Provider Relations for 
Underserved Populations. 
Although providing quality health insurance to 
all would be a huge step forward, not all cancer 
disparities would be resolved (Bach, Schrag et 
al. 2002). Pacific Islander and other minority 
cancer patients described increased problems 
with coordination of care, access to care, and 
dissemination and understanding of health and 
treatment related information (Ayanian, 
Zaslavsky et al. 2005; Tanjasiri, Kagawa Singer 
et al. 2002).  These problems were significantly 
worse amongst non-English speaking cancer 
patients. Not surprisingly, provider-patient 
communication has been identified as an 
important factor in patient’s decision making on 
participation in clinical trials (Albrecht, Eggly, 
et al. 2008). A patient’s sense of trust and 
confidence in their treating physician was 
significantly associated with the patients’ 
decision to participate in a clinical trial.  
Decreasing language and cultural barriers in 
provider-patient relationships would likely 
improve minority participation in cancer clinical 
trials. 
 
Integration and education of the cancer care 
work force are two measures that may help to 
decrease cultural and language barriers. 
Unfortunately, only 13% of U.S. medical 
students are African American, 
Hispanics/Latinos, or Native Americans, even 
though these populations comprise 25% of the 
total U.S. population (AAMC 2005). At the 
University of California medical schools, only 
17% of the 2005 new enrollments were African 
American, Hispanics/Latino, or Native 
Americans despite California having a much 
larger proportion of minorities compared to the 
overall U.S. population (Blumenthal 2007). 
Minority medical school graduates are also more 
likely to work in underserved areas (AAMC 
2005). Increased enrollment of minorities in 
medical schools also gives Caucasian students 
the opportunity to interact with persons of 
different cultures and backgrounds, thus, better 
preparing them for the increasingly diverse 
patient populations that they will serve (Saha, 
Guiton et al. 2008). In order to increase the 
proportion of qualified minority candidates for 
health professional schools, continued efforts, as 
described in this journal by Tran et al., must be 
made to cultivate future health care 
professionals. 
 
Cultural competency education is another 
method that is being utilized to facilitate 
improved patient-provider interactions for 
Pacific Islanders (Palafox, Buenconsejo-Lum et 
al. 2001). Recently, the Liaison Committee on 
Medical Education (LCME) mandated that all 
medical schools in the United States and Canada 
include cultural competency among their central 
educational outcomes (LCME 2007). However, 
how to define, implement and quantify adequate 
cultural competency education is still unclear 
(Gregg and Saha 2006; Kumagai and Lypson 
2009). As defined by Kumagai and Lypson, 
“cultural competency is not an abdominal exam. 
It is not a static requirement to be checked off 
some list but is something beyond the somewhat 
rigid categories of knowledge, skills, and 
attitudes: the continuous critical refinement and 
fostering of a type of thinking and knowing—a 
critical consciousness—of self, others, and the 
world…the outcome is therefore one of social 
justice—the open acknowledgment of the 
dignity and autonomy of, and delivery of high-
quality medical care to, all members of society, 
regardless of gender, race, ethnicity, religion, 
sexual orientation, language, geographic origin, 
or socioeconomic background (page 782-3).” 
These are standards that all health care 
professionals should uphold. Therefore, the 
promotion and perpetuation of these values in 
health professional schools is an area that also 
needs continued discussion and research. 
 
Although providing quality health insurance to 
all and increasing diversity and cultural 
competency of the cancer work force would 
reduce cancer disparities, other determinants of 
health such as socioeconomic status, education, 
and environmental factors still need to be 
addressed. Thus, many of the factors influencing 
health in underserved populations lie outside of 
the simple access and delivery of health care. 
Perhaps by enhancing our understanding of 
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determinants that lead to poor health and/or 
inadequate health care we may provide the 
ammunition needed by local communities to 
demand changes in laws and other policies at the 
local and national level. 
 
Conclusion 
 
Science will continue to unravel cancer biology. 
As we correlate these findings with 
race/ethnicity it may give us some insight into 
links between our diet, behaviors, environments 
and carcinogenesis. We must continue to work 
to increase participation of underserved 
populations in clinical trial research in order to 
identify determinants of cancer health 
disparities. Only then will we be able to enact 
preventive measures or targeted therapies to 
reduce these disparities. However, as we become 
more of a global community with a continually 
increasing proportion of multiracial/multiethnic 
people, the use of racial/ethnic classification 
may become less informative as a surrogate for 
non biologic determinants. Conversely, a more 
multiethnic/multiracial society may be more 
equipped and better able to bridge the complex 
barriers leading to cancer health disparities for 
Pacific Islanders and other ethnic/racial groups 
that exist today. 
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